Cellectar reports financial results for year ended 2022 and provides a corporate update

Florham park, n.j., march 09, 2023 (globe newswire) -- cellectar biosciences, inc. (nasdaq: clrb), a late-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted treatments for cancer, today announced financial results for the year ended december 31, 2022 and provided a corporate update.
CLRB Ratings Summary
CLRB Quant Ranking